Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Norovirus Interacts with Gut Bacteria to Establish a Persistent Infection That Can Be Blocked by Interferon Lambda

By LabMedica International staff writers
Posted on 27 Jan 2015
A team of molecular microbiologists and virologists has found that norovirus requires an intimate interaction with certain gut bacteria to establish a persistent infection, and that the infective process can be blocked by the immune factor interferon lambda (INFlambda).

Norovirus causes more than 90% of global epidemic nonbacterial gastroenteritis, and it is thought to be spread by a subset of people who maintain a low-level persistent infection. More...
How the enteric virus establishes such persistent infections is not well understood.

Investigators at Washington University School of Medicine (St. Louis, MO, USA) have turned up some interesting new insights regarding how norovirus infection becomes established and is maintained. They reported in the November 27, 2014, online edition of the journal Science that establishment of the viral infection in a mouse model depended on interaction with certain gut bacteria and that the infection could be prevented by treatment with antibiotics. Viral infection could be established following replenishment of the bacterial microbiota. Antibiotics did not prevent tissue infection or affect systemic viral replication, but acted specifically in the intestine.

In a second paper in the same issue of the journal Science, the investigators reported that while the cytokines interferon alpha (IFNalpha) and interferon beta (IFNbeta) prevented the systemic spread of norovirus in the mouse model, only IFNlambda controlled persistent enteric infection. Infection-dependent induction of IFNlambda was governed by the viral capsid protein and correlated with diminished enteric persistence. Treatment of established infection with IFNlambda cured mice in a manner that required non-hematopoietic cell expression of the IFNlambda receptor, Ifnlr1, and was independent of adaptive immunity.

“I believe that is a new concept in immunology,” said senior author Dr. Herbert W. Virgin, professor of pathology and immunology at Washington University School of Medicine. “We thought that interferon lambda and other related molecules in the immune system could only contain viral infections until other parts of the immune system, including antibodies and T-cells, finished the job.”

“The virus actually requires the bacteria to create a persistent infection,” said Dr. Virgin. “The virus appears to have a symbiotic relationship with the bacteria — they share the job of establishing persistence. We need a much more detailed understanding of how antibiotic treatment affects the links among host, bacteria, and virus.”

Related Links:

Washington University School of Medicine



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.